Hepatitis/MASH

The World Health Organization indicates that 35 million individuals have HIV worldwide, and 4 to 5 million HIV-infected patients are co-infected with hepatitis C virus.

FDA decision expected in second half of 2016.

Study finds potential link between HCV treatment and drug-induced hepatotoxicity.

Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.

A new study shows that adding a third drug to the ingredients in Harvoni could cure hepatitis C in half the ordinary time.

In California, a class action lawsuit has been filed on behalf of thousands of Blue Cross beneficiaries living with hepatitis C who were denied treatment.

One-step test will screen, detect and confirm a hepatitis C virus infection.

Near-fatal car accident leads man down long journey from infection to cure for hepatitis C.

Some of the basic research behind NS5B inhibitors reveals an often overlooked, but clinically important difference between Viekira Pak and Harvoni.

Extrahepatic manifestations may be important clues in the diagnosis of hepatitis C infection.

Effective therapies in liver transplant patients reduces HCV recurrence.

Patients on Medicaid more likely to have HCV infection and much more likely to be denied coverage.

Number of infected people is projected to drop below 1 million by 2020, but with substantial HCV disease and death burden.

Antiretroviral drug interactions now included due to high prevalence of HIV coinfection among patients with hepatitis C virus.

How treatment with Harvoni changed the life of a patient infected with HCV.

Patients simultaneously registering at multiple centers had higher transplant rates, lower death rates waiting for a transplant, and greater income.

Side effects, familial support and liver condition among factors that influence hepatitis C treatment decisions.

HCV drug combination may cut treatment time by 75%.

Direct-acting antivirals may help eradicate hepatitis C virus in patients who recently had a liver transplant, reducing the need for further transplants.

Combination of sofosbuvir and simeprevir may have an unexpected side effect in HCV therapy.

Lawsuits challenge access denials to curative hepatitis C drugs among incarcerated individuals infected with the disease.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Once-daily combination would be the first all-oral, pan-genotypic single tablet for treatment of HCV.